ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

ClinicalTrials.gov ID: NCT06593600

Public ClinicalTrials.gov record NCT06593600. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 3:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome

Study identification

NCT ID
NCT06593600
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
82 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • REGN7544 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2024
Primary completion
Apr 12, 2026
Completion
Jul 5, 2026
Last update posted
May 3, 2026

2024 – 2026

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
Mercy Gilbert Medical Center Gilbert Arizona 85297
North County Neurology Associates Carlsbad California 92011
Stanford University Palo Alto California 94304
Southern California Heart Specialists Pasadena California 91105
Yale University New Haven Connecticut 06511
Innovative Research of West Florida, Inc. Clearwater Florida 33756
Indiana University Health Neuroscience Center Indianapolis Indiana 46202
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Mayo Clinic Rochester Minnesota 55905
Saint Luke's MidAmerica Heart Institute Kansas City Missouri 64111
New York University Langone New York New York 10016
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104
Vanderbilt University Medical Center Nashville Tennessee 37232
University of Texas Southwestern Dallas Texas 75390
University of Utah Salt Lake City Utah 84108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06593600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06593600 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →